AstraZeneca’s offer price is $2.07 per share, the company said in an Oct. 3 news release, making the premium 660 percent and the total purchase price $68 million, according to the Boston Business Journal. Both boards of directors have approved the transaction, which is planned to finalize within four to six weeks.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
